ESG401
As of the edition of 20 October 2026, ESG401 is a drug known only by a code name: in active development; acts on TACSTD2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2025
- Kind
- Code name only
- Registered trials
- 3, 0 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Digestive system; Hormones; Lungs and airways; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TACSTD2 | Tumor-associated calcium signal transducer 2 | P09758 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 2 | 0 | 2 | 0 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Escugen Biotechnology | Lead sponsor of trials | 2021 to now |
| Qilu Pharmaceutical | Lead sponsor of trials | 2024 to now |